Nutritional Status Impacts Quality of Life in Head and Neck Cancer Patients Undergoing (Chemo)Radiotherapy: Results from the Prospective HEADNUT Trial. (25th July 2022)

• Record Type: Journal Article
• Authors: Löser, Anastassia; Avanesov, Maxim; Thieme, Alexander; Gargioni, Elisabetta; Baehr, Andrea; Hintelmann, Katharina; Tribius, Silke; Krüll, Andreas; Petersen, Cordula
• Is Part Of: Nutrition and cancer. Volume 74:Number 8(2022)
• Page Start: 2887
• Page End: 2895
• Publication Date: 2022-07-25
• Subjects: Cancer -- Periodicals; Nutrition -- Periodicals; Cancer; Nutrition; Periodicals; 616.9940654
• DOI: 10.1080/01635581.2022.2042571
• Languages: English
• ISSNs: 0163-5581

Abstract

Abstract: Malnutrition negatively impacts quality of life (QoL) in patients with head and neck cancer (HNC). This is the first prospective study to assess the impact of malnutrition (defined by the bioelectrical impedance analysis (BIA)-derived fat-free mass index) on QoL in patients with HNC undergoing (chemo)radiotherapy. Between October 2018 and October 2020, 58 HNC patients prospectively completed the QoL-questionnaires EORTC-QLQ-C30 and EORTC-QLQ-H&N35 at the beginning (tb ) and at the end of (chemo)radiotherapy (te ) as well as during follow-up (tf ). At these time points, nutritional risk assessment (MUST, NRS-2002, Nutriscore), BIA measurement and laboratory testing was performed by a permanent study team. Differences between malnourished ( n = 14) and well-nourished patients ( n = 44) were observed in UICC classification ( P < 0.001) and HPV status ( P = 0.03). Well-nourished patients showed higher baseline hemoglobin ( P = 0.025) and albumin ( P = 0.005), but lower c-reactive protein levels ( P < 0.001). At tb, mostly malnourished patients presented with worse QoL. Multivariable analysis showed that MUST, NRS-2002, HPV status, and UICC classification were related to QoL. Nutritional status has a crucial impact on QoL. The nutritional screening protocols MUST and NRS-2002 are suitable for identifying patients at risk and predicting QoL in patients with HNC undergoing (chemo)radiotherapy.